Completed PHASE1 INTERVENTIONAL 1-arm NCT00736593

A Study Evaluating Nexagon™ in the Treatment of Skin Wounds.

A Phase 1 Randomized, Prospective, Within-Subject, Double-Blind, Vehicle-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Clinical Effect of Nexagon™ in Full-Thickness Punch Wounds

Sponsor: OcuNexus Therapeutics, Inc.

Conditions Wound Healing

Interventions Nexagon™ or Nexagon™ vehicle

Updated 6 times since 2017 Last updated: Apr 23, 2009 Started: Sep 30, 2008 Primary completion: Jan 31, 2009 Completion: Apr 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Wound Healing and is currently completed. OcuNexus Therapeutics, Inc. leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Aug 2018 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Aug 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

OcuNexus Therapeutics, Inc.

Data source: OcuNexus Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Auckland, New Zealand